Category Archives: MS Treatment

Washington, Sept. 28 (ANI): Researchers have discovered a vitamin D-based treatment that can halt - and even reverse - the course of the disease in a mouse model of Multiple Sclerosis (MS). The treatment involves giving mice that exhibit MS symptoms a single dose of calcitriol, the active hormone form of vitamin D, followed by ongoing vitamin D supplements through the diet. Lead scientist biochemistry professor Colleen Hayes said that all of the animals just got better and better, and the longer we watched them, the more neurological function they regained. While scientists don't fully understand what triggers MS, some studies have linked low levels of vitamin D with a higher risk of developing the disease. Hayes has been studying this "vitamin D hypothesis" for the past 25 years with the long-term goal of uncovering novel preventive measures and treatments. Over the years, she and her researchers have revealed some of the molecular mechanisms involved in vitamin D's protective actions, and also explained how vitamin D interactions with estrogen may influence MS disease risk and progression in women. First, Hayes' team compared the effectiveness of a single dose of calcitriol to that of a comparable dose of a glucocorticoid, a … Continue reading →

MEQUON, Wisc.--(BUSINESS WIRE)-- ENDECE Neural today announced that it has entered into a sponsored research agreement for funding from the National Multiple Sclerosis Society through Fast Forward. Under the terms of the agreement ENDECE Neural will receive funding to advance the preclinical development of the companys lead compound, NDC-1308. If successfully developed into a therapeutic, NDC-1308 could provide physicians with a treatment to restore and repair the protective covering surrounding axons (nerve fibers) in the brain and spinal cord. ENDECE Neural will use the $225,000 in funding to validate preliminary data suggesting that NDC-1308 can restore and repair the axons protective covering, which is known as the myelin sheath. NDC-1308 demonstrated the ability to significantly remyelinate the myelin sheath in mice. The validation study will repeat the testing using an optimized formulation to determine how robustly NDC-1308 can stimulate remyelination in different regions of the mouse brain. ENDECE Neural also announced today that researchers will present data from preclinical trials of NDC-1308 at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The oral presentation, titled, NDC-1308 induces remyelination in experimental models of multiple sclerosis, is scheduled for Friday, Oct. 4 … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, Opexas President and Chief Executive Officer, will deliver a corporate presentation at the Aegis Capital Corp. 2013 Healthcare Conference. The conference will be held September 25-28th at The Encore at Wynn Las Vegas. Opexas presentation will occur at 8:30 a.m. (PDT) on Friday, September 27, 2013, and will include an overview of the Companys ongoing clinical development program for Tcelna, the Companys lead therapy for MS. About Opexa Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells isolated from the patients peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. About Multiple Sclerosis (MS) Multiple Sclerosis is a chronic, inflammatory condition of the central … Continue reading →

Denver, Colorado (PRWEB) September 26, 2013 http://www.SclerosisTreatment.com reveals that this new healing method actually is a remarkable cure for multiple sclerosis. This impressive healing plan is the result of years of work, as its creator Dr. Gary M. Levin claims. According to Dr. Levins own testimony, the specialist decided to start his own research with the main purpose to find a unique method of curing multiple sclerosis, as he wanted to be able to help his patients feel better. For this purpose to be achieved, the author of this new method had to focus on tracing the cause of multiple sclerosis first. To read the full review go to: http://www.sclerosistreatment.com/2013/02/multiple-sclerosis-natural-treatment.html In fact, this is what the treatment does: traces the cause of multiple sclerosis to eliminate it forever. Once the cause is gone, patients will experience gradual symptoms relief. In his complex eBook, Dr. Gary M. Levin also explains how this condition is developed. According to him the real problem patients are dealing with is an overactive immune system. This is why the specialist proposes a series of methods to improve the immune systems ability to recognize the fact that it is not working properly. In the Natural MS Treatment … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that new data from its Aubagio (teriflunomide) and Lemtrada (alemtuzumab) clinical development programs will be presented during the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS) to be held in Copenhagen, Denmark, October 2-5. The Challenges of Disease Management in MS: Navigating the Changing Landscape The recent European Commission approvals of Aubagio and Lemtrada make this years ECTRIMS particularly significant for Genzymes MS Franchise, said Genzyme CEO and President David Meeker. As we prepare to launch both products, we look forward to presenting these new data, which highlight the unique potential of our products to treat a broad spectrum of relapsing remitting MS patients and reflect our strong commitment to the MS community. Presentations at ECTRIMS/RIMS featuring Aubagio and Lemtrada are as follows. Aubagio: Oral Platform Presentation Poster Presentations Lemtrada: Poster Presentations Abstracts are available on the ECTRIMS/RIMS website. Read the original: Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS … Continue reading →

Elizabeth Toy, 29. A Cutchogue woman who had been battling Stage IV Hodgkins lymphoma for three years has died, friends said. Elizabeth Toy passed away Tuesday, Sept. 24 while receiving treatment at Stony Brook University Medical Center. She was 29. Ms. Toy was diagnosed in 2010 with Hodgkins lymphoma, a type of blood cancer that erodes the lymphatic system. As the disease progresses it compromises the bodys ability to fight infection, according to the Mayo Clinic. During her treatment, Ms. Toy remained a dedicated mother to her 11-year-old son, Matthew, friends said. She fought so hard to be here for him, longtime friend Tanya McDowell said. In her memory, Ms. McDowell has teamed up with Mattituck restaurant Four Doors Down to hold a fundraiser for Matthew. The money will be deposited into a trust fund he can access to pay for college, Ms. McDowell said. This will be a nest egg for him, she said. He can use it to start his life. Matthew is now in the custody of Ms. Toys mother, Ms. McDowell said. Continue reading here: Cutchogue mom loses her battle with blood cancer … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/jwg2ns/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at a CAGR of 3.16 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rising diagnosis and treatment rates. The Global MS Therapeutics market has also been witnessing the emergence of biomarkers. However, the lack of therapies available to manage the progression of the disease could pose a challenge to the growth of this market. The key vendors dominating this space include Bayer HealthCare AG, Biogen Idec Inc., Merck Serono SA, Novartis AG, and Teva Pharmaceutical Industries Ltd. The other vendors mentioned in this report are AB Science, Abbvie Inc., Active Biotech AB, Astra Zeneca plc, Glaxo Smith Kline plc, Glenmark Pharmaceuticals Ltd., Hoffmann-La Roche Inc., and Sanofi SA. Commenting on the report, an analyst from the team said: Currently, there is an increase in the adoption of biomarkers that are 100 percent specific to RRMS conditions. The use of biomarkers proves to be a sensitive indicator of the slightest disease activity in MS patients. A highly … Continue reading →

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) today announced that key data from the Companys multiple sclerosis (MS) franchise will be featured in over 20 presentations at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5, 2013. Data presentations will provide new clinical insights on the effects of treatment with COPAXONE (glatiramer acetate injection), the worlds leading relapsing-remitting multiple sclerosis (RRMS) treatment, and the novel effects of laquinimod, Tevas investigational oral compound, when used to treat RRMS. "With our sixteen year legacy in providing a safe and effective treatment for RRMS, Teva continues to discover and develop treatments that positively impact patients living with this complex, debilitating disease, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical Industries Ltd. The continued investigation of the long-term open-label study of COPAXONE and investigation of laquinimods effect in MS demonstrate our ongoing focus on increasing the body of scientific knowledge available to neurologists for making appropriate treatment decisions in a rapidly evolving landscape. In addition to presenting data at the Congress, Teva will host two satellite symposia, Emerging Insights in Multiple Sclerosis: Re-evaluating the Treatment Algorithm … Continue reading →

Sept. 26, 2013 A diagnosis of multiple sclerosis (MS) is a hard lot. Patients typically get the diagnosis around age 30 after experiencing a series of neurological problems such as blurry vision, wobbly gait or a numb foot. From there, this neurodegenerative disease follows an unforgiving course. Many people with MS start using some kind of mobility aid cane, walker, scooter or wheelchair by 45 or 50, and those with the most severe cases are typically bed-bound by 60. The medications that are currently available don't do much to slow the relentless march of the disease. In search of a better option for MS patients, a team of UW-Madison biochemists has discovered a promising vitamin D-based treatment that can halt and even reverse the course of the disease in a mouse model of MS. The treatment involves giving mice that exhibit MS symptoms a single dose of calcitriol, the active hormone form of vitamin D, followed by ongoing vitamin D supplements through the diet. The protocol is described in a scientific article that was published online in August in the Journal of Neuroimmunology. Hayes' team compared various vitamin D-based treatments to standard MS drugs. In each case, vitamin D-based treatments … Continue reading →

New four-year data will show continued Gilenya treatment reduced brain volume loss in MS patients compared to delaying treatment with Gilenya by two years Data will strengthen the link between brain volume loss and disability progression, highlighting the importance of reducing brain volume loss in patients with MS Real-world patient data will confirm superiority of Gilenya compared to standard therapies (interferon and glatiramer acetate) in reducing MS relapse rates Basel, September 25, 2013 - New data showing the benefits of Gilenya (fingolimod) on patient outcomes in multiple sclerosis (MS) will be presented at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, adding to the growing evidence base for Gilenya in both clinical trial and real-world settings. New four-year data from the pivotal FREEDOMS and FREEDOMS extension studies plus a separate analysis of three studies (FREEDOMS, FREEDOMS II and TRANSFORMS) will show the benefits of continued Gilenya treatment on brain volume loss compared to delayed treatment of two years. These data will reinforce what we know about the correlation between brain volume loss and disability, underlining the need for effectively addressing brain volume loss in patients with MS. Data from international … Continue reading →